ValThera is developing a novel transcatheter treatment for patients affected by Tricuspid valve diseases
1 of 2
Simplicity, Safety and Efficiency
Our solution for tricuspid valve regurgitation ("TR") is transvenous, easily deployed, and restores long-term effective function of the tricuspid valve